RCUS: Major October data update for casdatifan aims to boost confidence in pivotal renal cancer trials
Significant data updates for casdatifan in renal cell carcinoma are expected in October, covering late-line, second-line, and frontline settings. Pivotal studies are progressing well, with first data readouts anticipated in 2028 and a strong focus on commercial expansion and AI-driven drug discover…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.